




Supplementary Figures



Supplementary figure 1: representative healthy, BHD- and mOL-HDF-EV FACS Guava analysis of the main markers for exosomes (CD86), platelets (CD62P), monocytes/macrophages (CD14), T-cells (CD3), B-cells (CD40) and endothelial cells (CD144). Staining with the different antibodies (gray-filled curves) was compared to internal control (bright-line curve) represented by appropriate secondary isotype incubation



Supplementary figure 2: representative healthy, BHD- and mOL-HDF-EV FACS Guava analysis of molecules involved in inflammation, atherosclerosis, complement and coagulation activation: Membrane Attack Complex/ Terminal Complement Complex (C5b-9), Tissue Factor (Tiss. Factor), CD40-Ligand (CD40-L), Inducible T-cell COStimulator (ICOS), and Fas-Ligand (Fas-L). Staining with the different antibodies (gray-filled curves) was compared to internal control (bright-line curve) represented by appropriate secondary isotype incubation



Supplementary figure 3: Levels of expression of miR-223 in all experimental conditions in the *in vitro* angiogenesis and apoptosis assays. Results are expressed as mean \pm 1SD of three different experiments. AntagomiR-223 = inhibitor.

Table 1S (Supplementary Material): list of primers used for miRNA identification in plasma EV and for RUNX2 mRNA quantification in VSMC.

PRIMER	SEQUENCE
hsa-miR-17a-5p	5'- CAA AGT GCT TAC AGT GCA GGT AG -3'
hsa-miR-92a	5'- TAT TGC ACT TGT CCC GGC CTG T -3'
hsa-miR-223	5'- TGT CAG TTT GTC AAA TAC CCC A -3'
hsa-miR-423-5p	5'- TGA GGG GCA GAG AGC GAG -3'
hsa-miR-451	5'- AAA CCG TTA CCA TTA CTG AGT T -3'
hsa-RNU-48	5'- AAC TCT GAG TGT GTC GCT GAT G -3'
RUNX2 forward	5'-GAG TCC GGC CCC TCC AT-3'
RUNX2 reverse	5'-GCA ACT AAG TCA TAG TCC GCC TAG A-3'
Actin-β forward	5'-GAG TCC GGC CCC TCC AT-3'
Actin-β reverse	5'-GCA ACT AAG TCA TAG TCC GCC TAG A-3'